Zhao Yufeng, Cao Yirui, Su Ying, Chen Juntao, Wang Xuanchuan, Ding Peipei, Hu Weiguo, Zhu Tongyu, Hu Chao
Department of Kidney Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Mol Biol Rep. 2025 Mar 27;52(1):345. doi: 10.1007/s11033-025-10414-5.
Ischemia reperfusion injury (IRI) is an unavoidable condition that primarily affects graft function in renal transplantation. Blockage of complement activation by complement receptor immunoglobulin/ factor H (CRIg/FH), a novel complement inhibitor, shows great potency to ameliorate renal IRI. Sublytic membrane attack complex (MAC) disrupts cellular functions via the activation of different protein kinases and phosphorylation of critical signal transduction factors. We aimed to investigate whether complement activation triggered shift in phosphorylation status in IRI.
We performed a LC-MS/MS-based quantitative phosphoproteomic analysis of CRIg/FH-IRI, PBS-IRI and Sham mice, depicting a thorough protein phosphorylation profile. C3d and MAC staining were conducted to study the complement activation status. In vitro model mimicking complement mediated IRI tubular injury was achieved by applying normal human serum (NHS) to TCMK cells. By hierarchical clustering, we observed that CRIg/FH treatment reversed the hyperphosphorylation status triggered by IRI. Differentially expressed phosphoproteins (DEPs) were associated with focal adhesion, integrin activation, actin cytoskeleton organization and cell junction. We identified c-Jun as the most differentially phosphorylated transcriptional factor regulated by complement activation, the S63 phosphorylation of which was verified both in vitro and in vivo and screened for its downstream targets. JNK inhibitor reduced the phosphorylation of c-Jun and attenuated accumulation of the C3d on the tubular epithelial cells.
We proposed a crucial role of c-Jun phosphorylation in complement activation induced by renal IRI by combining phosphoproteomic approaches and protein validation, which hopefully could provide novel insights into the pathological mechanisms of IRI.
缺血再灌注损伤(IRI)是肾移植中不可避免的一种情况,主要影响移植肾的功能。新型补体抑制剂补体受体免疫球蛋白/因子H(CRIg/FH)阻断补体激活,在改善肾IRI方面显示出强大的效力。亚溶膜攻击复合物(MAC)通过激活不同的蛋白激酶和关键信号转导因子的磷酸化来破坏细胞功能。我们旨在研究补体激活是否会引发IRI中磷酸化状态的改变。
我们对CRIg/FH-IRI、PBS-IRI和假手术小鼠进行了基于液相色谱-串联质谱的定量磷酸化蛋白质组分析,描绘了全面的蛋白质磷酸化图谱。进行C3d和MAC染色以研究补体激活状态。通过将正常人血清(NHS)应用于TCMK细胞,建立了模拟补体介导的IRI肾小管损伤的体外模型。通过层次聚类,我们观察到CRIg/FH治疗逆转了IRI引发的高磷酸化状态。差异表达的磷酸化蛋白(DEPs)与粘着斑、整合素激活、肌动蛋白细胞骨架组织和细胞连接有关。我们确定c-Jun是受补体激活调节的差异磷酸化最明显的转录因子,其S63磷酸化在体外和体内均得到验证,并筛选了其下游靶点。JNK抑制剂降低了c-Jun的磷酸化,并减弱了C3d在肾小管上皮细胞上的积累。
我们通过结合磷酸化蛋白质组学方法和蛋白质验证,提出了c-Jun磷酸化在肾IRI诱导的补体激活中的关键作用,这有望为IRI的病理机制提供新的见解。